Deans' stroke musings: BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, April 19, 2013

BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke

No human clinical trials yet so you will need to depend on your doctors analysis if this is worth trying.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=73295#.UXFxond9CpI
BioTime Inc. (NYSE MKT: BTX) today announced that it has entered into an exclusive license agreement with the University of California Los Angeles (UCLA) for novel technology related to the treatment of stroke. The licensed technology developed in the laboratories of Tom Carmichael MD PhD of UCLA’s Department of Neurology at the David Geffen School of Medicine uses one of BioTime’s HyStem® hydrogels to deliver locally released growth factors to improve recovery from stroke. Pre-clinical studies have demonstrated that the localized delivery of growth factors such as brain-derived neurotrophic factor (BDNF) results in a statistically significant improvement in post-stroke motor function in a murine model of ischemic stroke.
Concurrent with the execution of this exclusive license agreement BioTime has entered into a Sponsored Research Agreement with UCLA to support on-going pre-clinical work in Dr. Carmichael’s laboratory to advance the understanding of this technology and develop data in support for the potential filing of an Investigational New Drug Application (IND) for human clinical trails.